
    
      This study is a double-blind, repeat-dose, randomized, multicenter, two-part, parallel-group,
      dose-ranging study of arformoterol and placebo in the treatment of subjects with COPD.
      Approximately 215 subjects will be randomized in this study. Study participation will consist
      of a total of eight (8) study visits over approximately ten (10) weeks for each subject. This
      study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by
      Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    
  